CV-8102

DB19184InvestigationalProtein Based Therapies

CV-8102 is under investigation in clinical trial NCT03203005 (IMA970A Plus CV8102 in Very Early, Early and Intermediate Stage Hepatocellular Carcinoma Patients).

Mechanism: Pharmacologically active on Toll-like receptor 7, Toll-like receptor 8, and Antiviral innate immune response receptor RIG-I
Curator reviewed
Also known as: Rna-based adjuvant cv8102 · RNADJUVANT · Ssrna-based immunomodulator cv8102
Code names: CV-8102

Resolves to

Compound

UNIIULM5THL8W5

Targets

Q9NYK1TLR7Q9NR97TLR8O95786RIGI

What you can answer from here — as of July 09, 2026

3Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

3Clinical trialsPhase, status and sponsor resolved per trial

9+ReferencesStructured and connected to the statements they support

Which drugs share a target with CV-8102, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account